Companies in #Immuno-Oncology

BioAtla is a clinical-stage biopharmaceutical company developing novel antibody and cell-based therapeutics for solid tumors using its proprietary Conditionally Active Biologics (CAB) platform, which exploits the tumor microenvironment to improve therapeutic index. Lead programs include mecbotamab vedotin (BA3011), a CAB-AXL antibody-drug conjugate (ADC) in clinical development for undifferentiated pleomorphic sarcoma and non-small cell lung cancer, and ozuriftamab vedotin (CAB-ROR2-ADC), targeting ROR2-expressing tumors. The company initiated a strategic review in March 2026; in August 2026 the Nasdaq Listing Council affirmed a delisting determination and the common stock is expected to transition to OTC Markets trading effective August 31, 2026.

Clinical-stage biopharmaceutical company using AI to identify and develop novel therapies in neuroscience and immuno-oncology. Filed for bankruptcy in August 2026 and agreed to sell assets to Teva Pharmaceutical for up to $125M.

Clinical-stage biotechnology company developing RNA-based immune activators that turn cold tumors hot, led by intralesional BO-112 for skin tumors and other solid tumors.

Commercial-stage biopharmaceutical company developing gene and cell therapies for difficult-to-treat diseases, with a focus on immuno-oncology and precision medicine; its AdenoVerse immunotherapeutic platform received FDA platform technology designation in September 2026.

Pyxis Oncology is a clinical-stage company developing next-generation antibody-drug conjugates and immunotherapies for difficult-to-treat solid tumors. Its lead candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an antibody-drug conjugate that targets extradomain-B fibronectin, a structural component of the tumor extracellular matrix rather than a surface antigen on the cancer cell itself; it holds FDA Fast Track designation and is being evaluated in Phase 1 monotherapy cohorts and in a Phase 1/2 combination study with Merck's pembrolizumab, with recurrent and metastatic head and neck squamous cell carcinoma the focus indication. A portfolio prioritization narrowed development onto that lead program. Founded in 2018 as a spinout of Longwood Fund with an early licensing relationship with Pfizer, and headquartered in Boston, Massachusetts, the company went public on Nasdaq in October 2021. It remains pre-revenue and funds development from the balance sheet: on September 30, 2026 it priced a registered public offering of 36,047,919 common shares, or pre-funded warrants in lieu, paired with warrants for expected gross proceeds of approximately $110 million and up to $282.6 million if the accompanying warrants are exercised in full.

Shattuck Labs is a clinical-stage biotechnology company developing novel biotherapeutics based on its proprietary Agonist Redirected Checkpoint (ARC) platform, which combines elements of antibody and cytokine receptor signaling in single fusion proteins for the treatment of cancer and inflammatory disease.

Zymeworks is a clinical-stage biotechnology company developing multifunctional biotherapeutics for difficult-to-treat cancers. The company's platforms include Azymetric (bispecific antibodies) and EFECT (immune-effector modulation), and it is advancing multiple wholly-owned and partnered oncology candidates. In 2026 Zymeworks expanded its pipeline through the near-$1B acquisition of Theravance Biopharma, adding a lung-disease drug candidate plus royalty streams.